Håkan Martinell, Nordiska Centrumhus & Fredrik Almqvist, Quretech AB Foto: Jörgen Johansson
21.12.2018

Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn (made up of SEK 7.5 million from the Swedish Research Council, SEK 8 million from the Erling Persson Family Foundation and SEK 2.1 million from Umeå University).

These grants will contribute to new knowledge and a better understanding of the development of new alternatives in the fight against antibiotic resistance. The grants support both fundamental and applied research, both of which are crucially important to Quretech’s ability to develop new options for combating antibiotic resistant infections. Since 2014 Quretech Bio researchers have been awarded grants and capital totalling circa SEK 105 million, which means the future looks bright and exciting.

Quretech Bio AB is a research company based in Umeå, Sweden and St. Louis, USA, made up largely of researchers connected to Umeå University and Washington University in St. Louis. Quretech is active in three separate areas: reinforcement of available antibiotics against tuberculosis, the control of antibiotic resistance in VRE and MRSA (a type of ‘killer bacterium’) through new treatment principles and thirdly the neutralisation of other bacteria (for example chlamydia).

Back in 2014 Quretech’s researchers received a grant from the Knut and Alice Wallenberg Foundation of SEK 33 million which laid the foundation for today’s research. In the past six months researchers received approximately SEK 42 million of additional funds, including some SEK 24 million from US research financier the National Institutes of Health (NIH).

In addition Quretech has also welcomed Nordiska Centrumhus as an external investor to assist in business development issues where needed.

Håkan Martinell, CEO – Nordiska Centrumhus:

“We are very impressed with the results that Quretech has achieved so far. We want to thank the Knut and Alice Wallenberg Foundation, whose early support laid the foundation that enabled Quretech’s researchers to take their work to where it is today. A big thank you also to NIH, the Erling Persson Family Foundation, Novo Nordisk, The Kempe Foundations, the EU and not least the Swedish Research Council, whose combined support makes it possible to take research to the next level!

“We are also very grateful to Umeå University and Umeå Biotech Incubator, who through their long-term involvement have created the right conditions for local researchers in Umeå as well as their colleagues at Washington University in St. Louis.”

Fredrik Almqvist, CEO – Quretech Bio AB:

“We would like to thank everyone we have received support and funding from: The Knut and Alice Wallenberg Foundation, Umeå University, the Swedish Research Council, the Erling Persson Family Foundation, NIH in the USA, the EU, Novo Nordisk, the Strategic Foundation, Göran Gustafsson’s Foundation and The Kempe Foundations.”

 

“As researchers at Quretech we are also very grateful for the expertise that has been introduced into the company thanks to Nordiska Centrumhus. We’re looking forward to a very exciting journey together!”

 

For further information please contact:

Quretech Bio AB
Fredrik Almqvist, Founder and CEO of Quretech Bio AB
fredrik.almqvist@quretech.com
070-397 90 97
www.quretech.com

https://www.nordiskacentrumhus.se/quretech-bio-tar-sin-forsta-externa-investerare